- Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
- Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Connect Biopharma Announces New Leadership and Chair of the Board of Directors
- Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
- Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
- Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
- Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
- Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
- Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
- Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
More ▼
Key statistics
On Wednesday, Connect Biopharma Holdings Ltd (CNTB:NMQ) closed at 1.34, 150.61% above the 52 week low of 0.5347 set on Sep 21, 2023.
52-week range
Open | 1.36 |
---|---|
High | 1.39 |
Low | 1.30 |
Bid | 1.32 |
Offer | 1.55 |
Previous close | 1.38 |
Average volume | 134.60k |
---|---|
Shares outstanding | 55.10m |
Free float | 31.37m |
P/E (TTM) | -- |
Market cap | 76.04m USD |
EPS (TTM) | -1.08 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 17:59 BST.
More ▼